23 May 2013
Keywords: Gilead Sciences, YM BioSciences, M&A, Cancer drug candidate, CYT387
Article | 13 December 2012
US biotechnology firm Gilead Sciences (Nasdaq: GILD) has agreed to acquire Canada's YM BioSciences (TSX: YM) in a deal that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
13 November 2012
31 January 2013
16 November 2012
© 2013 thepharmaletter.com